Literature DB >> 31289117

A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.

Ruth Hüttenhain1, Meena Choi2, Laura Martin de la Fuente3, Kathrin Oehl4, Ching-Yun Chang5, Anne-Kathrin Zimmermann4, Susanne Malander3, Håkan Olsson3, Silvia Surinova6, Timothy Clough5, Viola Heinzelmann-Schwarz7, Peter J Wild8, Daniela M Dinulescu9, Emma Niméus10, Olga Vitek11, Ruedi Aebersold12.   

Abstract

Protein biomarkers for epithelial ovarian cancer are critical for the early detection of the cancer to improve patient prognosis and for the clinical management of the disease to monitor treatment response and to detect recurrences. Unfortunately, the discovery of protein biomarkers is hampered by the limited availability of reliable and sensitive assays needed for the reproducible quantification of proteins in complex biological matrices such as blood plasma. In recent years, targeted mass spectrometry, exemplified by selected reaction monitoring (SRM) has emerged as a method, capable of overcoming this limitation. Here, we present a comprehensive SRM-based strategy for developing plasma-based protein biomarkers for epithelial ovarian cancer and illustrate how the SRM platform, when combined with rigorous experimental design and statistical analysis, can result in detection of predictive analytes.Our biomarker development strategy first involved a discovery-driven proteomic effort to derive potential N-glycoprotein biomarker candidates for plasma-based detection of human ovarian cancer from a genetically engineered mouse model of endometrioid ovarian cancer, which accurately recapitulates the human disease. Next, 65 candidate markers selected from proteins of different abundance in the discovery dataset were reproducibly quantified with SRM assays across a large cohort of over 200 plasma samples from ovarian cancer patients and healthy controls. Finally, these measurements were used to derive a 5-protein signature for distinguishing individuals with epithelial ovarian cancer from healthy controls. The sensitivity of the candidate biomarker signature in combination with CA125 ELISA-based measurements currently used in clinic, exceeded that of CA125 ELISA-based measurements alone. The SRM-based strategy in this study is broadly applicable. It can be used in any study that requires accurate and reproducible quantification of selected proteins in a high-throughput and multiplexed fashion.
© 2019 Hüttenhain et al.

Entities:  

Keywords:  Cancer biomarker(s); ovarian cancer; plasma or serum analysis; quantification; selected reaction monitoring; statistics; targeted mass spectrometry

Mesh:

Substances:

Year:  2019        PMID: 31289117      PMCID: PMC6731088          DOI: 10.1074/mcp.RA118.001221

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  65 in total

1.  Linear models and empirical bayes methods for assessing differential expression in microarray experiments.

Authors:  Gordon K Smyth
Journal:  Stat Appl Genet Mol Biol       Date:  2004-02-12

2.  Diagnostic markers for early detection of ovarian cancer.

Authors:  Irene Visintin; Ziding Feng; Gary Longton; David C Ward; Ayesha B Alvero; Yinglei Lai; Jeannette Tenthorey; Aliza Leiser; Ruben Flores-Saaib; Herbert Yu; Masoud Azori; Thomas Rutherford; Peter E Schwartz; Gil Mor
Journal:  Clin Cancer Res       Date:  2008-02-07       Impact factor: 12.531

Review 3.  The role of biomarkers in the management of epithelial ovarian cancer.

Authors:  Wei-Lei Yang; Zhen Lu; Robert C Bast
Journal:  Expert Rev Mol Diagn       Date:  2017-05-15       Impact factor: 5.225

4.  Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine.

Authors:  Elodie Duriez; Christophe D Masselon; Cédric Mesmin; Magali Court; Kevin Demeure; Yves Allory; Núria Malats; Mariette Matondo; François Radvanyi; Jérôme Garin; Bruno Domon
Journal:  J Proteome Res       Date:  2017-03-23       Impact factor: 4.466

Review 5.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

6.  A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Authors:  Claire S Zhu; Paul F Pinsky; Daniel W Cramer; David F Ransohoff; Patricia Hartge; Ruth M Pfeiffer; Nicole Urban; Gil Mor; Robert C Bast; Lee E Moore; Anna E Lokshin; Martin W McIntosh; Steven J Skates; Allison Vitonis; Zhen Zhang; David C Ward; James T Symanowski; Aleksey Lomakin; Eric T Fung; Patrick M Sluss; Nathalie Scholler; Karen H Lu; Adele M Marrangoni; Christos Patriotis; Sudhir Srivastava; Saundra S Buys; Christine D Berg
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

7.  Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.

Authors:  Elieser Gorelik; Douglas P Landsittel; Adele M Marrangoni; Francesmary Modugno; Lyudmila Velikokhatnaya; Matthew T Winans; William L Bigbee; Ronald B Herberman; Anna E Lokshin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

8.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

9.  Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer.

Authors:  Igor Cima; Ralph Schiess; Peter Wild; Martin Kaelin; Peter Schüffler; Vinzenz Lange; Paola Picotti; Reto Ossola; Arnoud Templeton; Olga Schubert; Thomas Fuchs; Thomas Leippold; Stephen Wyler; Jens Zehetner; Wolfram Jochum; Joachim Buhmann; Thomas Cerny; Holger Moch; Silke Gillessen; Ruedi Aebersold; Wilhelm Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

10.  The TGFβ-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs.

Authors:  Andrew J Pellatt; Lila E Mullany; Jennifer S Herrick; Lori C Sakoda; Roger K Wolff; Wade S Samowitz; Martha L Slattery
Journal:  J Transl Med       Date:  2018-07-09       Impact factor: 5.531

View more
  10 in total

Review 1.  Prognostic utility of the ovarian cancer secretome: a systematic investigation.

Authors:  Pradnya R Kamble; Apoorva Pawar; Ananya A Breed; Grishma Kasle; Bhakti R Pathak
Journal:  Arch Gynecol Obstet       Date:  2022-01-27       Impact factor: 2.493

2.  Autoantibody signature in hepatocellular carcinoma using seromics.

Authors:  Shu Zhang; Yuming Liu; Jing Chen; Hong Shu; Siyun Shen; Yin Li; Xinyuan Lu; Xinyi Cao; Liangqing Dong; Jieyi Shi; Ya Cao; Xiaoying Wang; Jian Zhou; Yinkun Liu; Lei Chen; Jia Fan; Guangyu Ding; Qiang Gao
Journal:  J Hematol Oncol       Date:  2020-07-02       Impact factor: 17.388

3.  A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry.

Authors:  Daniel M Waldera-Lupa; Gereon Poschmann; Nina Kirchgaessler; Omid Etemad-Parishanzadeh; Falk Baberg; Mareike Brocksieper; Sabine Seidel; Thomas Kowalski; Anna Brunn; Aiden Haghikia; Ralf Gold; Anja Stefanski; Martina Deckert; Uwe Schlegel; Kai Stühler
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

Review 4.  Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review.

Authors:  Melissa Bradbury; Eva Borràs; Assumpció Pérez-Benavente; Antonio Gil-Moreno; Anna Santamaria; Eduard Sabidó
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

5.  Circulating proteomic panels for risk stratification of intracranial aneurysm and its rupture.

Authors:  Yueting Xiong; Yongtao Zheng; Yan Yan; Jun Yao; Hebin Liu; Fenglin Shen; Siyuan Kong; Shuang Yang; Guoquan Yan; Huanhuan Zhao; Xinwen Zhou; Jia Hu; Bin Zhou; Tao Jin; Huali Shen; Bing Leng; Pengyuan Yang; Xiaohui Liu
Journal:  EMBO Mol Med       Date:  2022-01-03       Impact factor: 12.137

Review 6.  Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.

Authors:  Shuvolina Mukherjee; Karin Sundfeldt; Carl A K Borrebaeck; Magnus E Jakobsson
Journal:  Proteomes       Date:  2021-05-25

Review 7.  Recent advances in mass spectrometry based clinical proteomics: applications to cancer research.

Authors:  Andrew Macklin; Shahbaz Khan; Thomas Kislinger
Journal:  Clin Proteomics       Date:  2020-05-24       Impact factor: 3.988

Review 8.  Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.

Authors:  Ruchika Bhawal; Ann L Oberg; Sheng Zhang; Manish Kohli
Journal:  Cancers (Basel)       Date:  2020-08-27       Impact factor: 6.639

Review 9.  Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.

Authors:  Joohyun Ryu; Stefani N Thomas
Journal:  Molecules       Date:  2021-05-03       Impact factor: 4.411

10.  A highly multiplexed quantitative phosphosite assay for biology and preclinical studies.

Authors:  Hasmik Keshishian; E Robert McDonald; Filip Mundt; Randy Melanson; Karsten Krug; Dale A Porter; Luke Wallace; Dominique Forestier; Bokang Rabasha; Sara E Marlow; Judit Jane-Valbuena; Ellen Todres; Harrison Specht; Margaret Lea Robinson; Pierre M Jean Beltran; Ozgun Babur; Meagan E Olive; Javad Golji; Eric Kuhn; Michael Burgess; Melanie A MacMullan; Tomas Rejtar; Karen Wang; D R Mani; Shankha Satpathy; Michael A Gillette; William R Sellers; Steven A Carr
Journal:  Mol Syst Biol       Date:  2021-09       Impact factor: 11.429

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.